Corrigendum to “Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: A Retrospective,Multicenter Study and Meta-Analysis of Existing Data”

John M. Cochran, Xiaoming Jia, Jessica Kaczmarek, Kristen A. Staggers, Mahmoud Al Rifai, Ihab R. Hamzeh, and Yochai Birnbaum. Direct oral anticoagulants in the treatment of left ventricular thrombus: a retrospective, multicenter study and meta-analysis of existing data. J Cardiovasc Pharmacol Therap 2021;26(2):173-178. DOI: 10.1177/1074248420967644

On page 175, Table 2 was published with an error. In the last row of Table 2, values in columns 2 and 3 were swapped. The correct table is given below.

Table 2.

Efficacy and Safety Outcomes of Direct Oral Anticoagulant (DOAC) or Vitamin K Antagonist (VKA) in the Treatment of Patients With Left Ventricular Thrombus.

	VKA, N (%)	DOAC, N (%)	P value
Bleeding events within 12 months	8 (13.6)	2 (14.3)	1
Clinical stroke within 12 months	9 (15.3)	0	.192
Acute coronary syndrome within 12 months	2 (3.4)	1 (7.1)	.477
Death within 12 months	2 (3.4)	1 (7.1)	.477
Thrombus resolution within 12 months	45 (76.3)	12 (85.7)	.721